Ftse Mib
34.374,77
0,55%
DAX
20.024,66
0,58%
S&P 500
5.868,55
-0,22%
NASDAQ
19.280,79
-0,16%
Bitcoin
96.977,54
0,08%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Foghorn Therapeutics Inc (FHTX) Foghorn Therapeutics Inc (FHTX) Notizie

FHTX

Foghorn Therapeutics (FHTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FHTX
DataOraFonteTitoloSimboloCompagnia
30/12/202413:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FHTXFoghorn Therapeutics Inc
16/12/202413:00GlobeNewswire Inc.Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic PrioritiesNASDAQ:FHTXFoghorn Therapeutics Inc
12/11/202413:54GlobeNewswire Inc.Foghorn Therapeutics to Participate in Three Upcoming Investor ConferencesNASDAQ:FHTXFoghorn Therapeutics Inc
04/11/202422:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FHTXFoghorn Therapeutics Inc
23/10/202414:00PR Newswire (US)Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering IntelligenceNASDAQ:FHTXFoghorn Therapeutics Inc
10/10/202413:00GlobeNewswire Inc.Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid TumorsNASDAQ:FHTXFoghorn Therapeutics Inc
08/10/202423:44Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:FHTXFoghorn Therapeutics Inc
03/10/202414:00PR Newswire (US)Invaio Sciences Appoints André Andonian as Chairman of the Board of DirectorsNASDAQ:FHTXFoghorn Therapeutics Inc
01/10/202413:00GlobeNewswire Inc.Foghorn Therapeutics to Participate in the BMO Oncology SummitNASDAQ:FHTXFoghorn Therapeutics Inc
24/09/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FHTXFoghorn Therapeutics Inc
16/09/202422:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FHTXFoghorn Therapeutics Inc
04/09/202422:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:FHTXFoghorn Therapeutics Inc
03/09/202413:00GlobeNewswire Inc.Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business OfficerNASDAQ:FHTXFoghorn Therapeutics Inc
28/08/202413:00GlobeNewswire Inc.Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberNASDAQ:FHTXFoghorn Therapeutics Inc
08/08/202414:44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FHTXFoghorn Therapeutics Inc
06/08/202412:30PR Newswire (US)Flagship Pioneering Announces Appointment of Raj Panjabi as Senior PartnerNASDAQ:FHTXFoghorn Therapeutics Inc
28/05/202413:00GlobeNewswire Inc.Foghorn Therapeutics to Participate in Upcoming Investor Conferences in JuneNASDAQ:FHTXFoghorn Therapeutics Inc
23/05/202400:21GlobeNewswire Inc.Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance PipelineNASDAQ:FHTXFoghorn Therapeutics Inc
06/05/202413:03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FHTXFoghorn Therapeutics Inc
07/03/202413:09Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:FHTXFoghorn Therapeutics Inc
28/11/202301:01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:FHTXFoghorn Therapeutics Inc
21/11/202312:00PR Newswire (US)Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsNASDAQ:FHTXFoghorn Therapeutics Inc
01/11/202315:30PR Newswire (US)Flagship Pioneering Launches Pioneering IntelligenceNASDAQ:FHTXFoghorn Therapeutics Inc
11/09/202312:30PR Newswire (US)Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerNASDAQ:FHTXFoghorn Therapeutics Inc
05/09/202314:00GlobeNewswire Inc.Foghorn Therapeutics Announces Participation in Upcoming Investor ConferencesNASDAQ:FHTXFoghorn Therapeutics Inc
31/08/202313:00GlobeNewswire Inc.Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AMLNASDAQ:FHTXFoghorn Therapeutics Inc
29/08/202315:00PR Newswire (US)Invaio achieves first registration for citrus greening solution featuring Trecise™ technologyNASDAQ:FHTXFoghorn Therapeutics Inc
08/08/202313:00GlobeNewswire Inc.Foghorn Therapeutics Announces Chief Medical Officer SuccessionNASDAQ:FHTXFoghorn Therapeutics Inc
04/08/202313:00GlobeNewswire Inc.Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate UpdateNASDAQ:FHTXFoghorn Therapeutics Inc
28/06/202313:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FHTXFoghorn Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FHTX

La tua Cronologia

TG
A3K1DD
NE Property
USOTC
ARCAY
Arcadis NV (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network